ClinicalTrials.gg
CompletedNCT02296853Updated Dec 9, 2020Results posted

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

A Phase 1 interventional study of TAF in Hepatitis B Virus, sponsored by Gilead Sciences. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing tenofovir alafenamide in Hepatitis B — 10 open to participants now, 12 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B.

Enrollment
21st of 21
20 · median 120
Started
2014
the only one that year
Phase 1
2 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
2 of 21
Gilead Sciences

Among the 21 studies testing tenofovir alafenamide in Hepatitis B, this one is the 21st largest by enrollment, is the only one that started in 2014, is one of 2 in phase 1, and was the 2nd registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

10 of the 21 studies testing tenofovir alafenamide in Hepatitis B are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tenofovir alafenamide in Hepatitis B, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.

03

Conditions studied

  • Hepatitis B Virus

Browse trials for

Keywords

  • Severe Hepatic Impairment
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Screening laboratory parameters within defined thresholds
  • must be ≥ 60 mL/min

Key Exclusion Criteria:

  • Females who are pregnant or nursing or males who have a pregnant partner
  • Infection with virus (HBV) or
  • History of illness (including psychiatric or cardiac) or any other medical disorder that may interfere with participant treatment and/or adherence to the protocol

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Severe Hepatic Impairment Group

    Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.

    Drug: TAF

  • Active comparator
    Matched Normal Hepatic Function Group

    Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.

    Drug: TAF

Interventions

  • DrugTAF

    25 mg tablet administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUCinf of Tenofovir Alafenamide (TAF), Its Metabolite Tenofovir (TFV) and Free (Unbound) TAF

    AUCinf is defined as the concentration of drug extrapolated to infinite time.

    Time frame: Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1

  2. PK Parameter: Cmax of TAF, Its Metabolite TFV and Free (Unbound) TAF

    Cmax is defined as the maximum concentration of drug.

    Time frame: Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1

  3. PK Parameter: AUClast of TAF, Its Metabolite TFV and Free (Unbound) TAF

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1

Secondary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are events that meet one of the following criteria: any AEs with onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

    Time frame: Day 1 plus 30 days

  2. Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. These were graded as Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: Day 1 plus 30 days

07

Results

Posted Dec 9, 2020

Participant flow

Participants were enrolled at study sites in Germany, New Zealand, and the United States. The first participant was screened on 22 December 2014. The last study visit occurred on 17 April 2015.

Participant flow — Overall Study
MilestoneSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUCinf of Tenofovir Alafenamide (TAF), Its Metabolite Tenofovir (TFV) and Free (Unbound) TAF

AUCinf is defined as the concentration of drug extrapolated to infinite time.

Time frame:
Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUCinf of Tenofovir Alafenamide (TAF), Its Metabolite Tenofovir (TFV) and Free (Unbound) TAF
h*ng/mLSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
TAF120.6 ± 33.96228.2 ± 85.30
TFV219.9 ± 118.70304.0 ± 72.45
Free (unbound) TAF42.8 ± 11.7646.5 ± 17.78
Statistical analysis
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 54.04 · 90% CI 41.98 to 69.56Here, GLSM is geometric least square mean.
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 63.06 · 90% CI 42.90 to 92.70
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 94.42 · 90% CI 72.48 to 122.99
PrimaryPK Parameter: Cmax of TAF, Its Metabolite TFV and Free (Unbound) TAF

Cmax is defined as the maximum concentration of drug.

Time frame:
Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK Parameter: Cmax of TAF, Its Metabolite TFV and Free (Unbound) TAF
ng/mLSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
TAF79.6 ± 39.31176.0 ± 79.77
TFV7.5 ± 3.957.6 ± 1.83
Free (unbound) TAF29.9 ± 17.3636.2 ± 18.38
Statistical analysis
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 45.10 · 90% CI 31.66 to 64.25
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 89.88 · 90% CI 64.77 to 124.72
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 82.16 · 90% CI 56.58 to 119.31
PrimaryPK Parameter: AUClast of TAF, Its Metabolite TFV and Free (Unbound) TAF

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUClast of TAF, Its Metabolite TFV and Free (Unbound) TAF
h*ng/mLSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
TAF113.1 ± 30.85225.7 ± 85.09
TFV184.2 ± 99.86256.7 ± 59.91
Free (unbound) TAF41.7 ± 11.1746 ± 17.75
Statistical analysis
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 51.20 · 90% CI 40.11 to 65.36
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 62.04 · 90% CI 41.92 to 91.82
  • Severe Hepatic Impairment Group vs Matched Normal Hepatic Function Group · Glsm ratio percentage: 93.28 · 90% CI 72.62 to 119.8
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

TEAEs are events that meet one of the following criteria: any AEs with onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

Time frame:
Day 1 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)40.030.0
SecondaryPercentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. These were graded as Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
Day 1 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities
percentage of participantsSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
Grade 140.030.0
Grade 240.030.0
Grade 320.010.0
Grade 400

Adverse events

Collected over Day 1 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severe Hepatic Impairment Group0/10 (0%)1/10 (10%)4/10 (40%)
Matched Normal Hepatic Function Group0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent serious events
Most frequent serious events
EventSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
Hepatic failureHepatobiliary disorders1/100/10
Most frequent other events
Most frequent other events
EventSevere Hepatic Impairment GroupMatched Normal Hepatic Function Group
NauseaGastrointestinal disorders0/102/10
HeadacheNervous system disorders1/102/10
Abdominal distensionGastrointestinal disorders1/100/10
VomitingGastrointestinal disorders0/101/10
FatigueGeneral disorders0/101/10
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/100/10
CoughRespiratory, thoracic and mediastinal disorders1/100/10
PruritusSkin and subcutaneous tissue disorders1/100/10

Baseline characteristics

The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Severe Hepatic Impairment GroupMatched Normal Hepatic Function GroupTotal
Mean57 ± 7.355 ± 9.356 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Severe Hepatic Impairment GroupMatched Normal Hepatic Function GroupTotal
Female5510
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Severe Hepatic Impairment GroupMatched Normal Hepatic Function GroupTotal
Hispanic or Latino347
Not Hispanic or Latino7613
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Severe Hepatic Impairment GroupMatched Normal Hepatic Function GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White10919
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Severe Hepatic Impairment GroupMatched Normal Hepatic Function GroupTotal
Germany134
New Zealand224
United States7512
08

Study locations

5 sites
  • Miami, Florida 33014, United States
  • Orlando, Florida 32809, United States
  • San Antonio, Texas 78215, United States
  • Munich, D-81241, Germany
  • Gratton, Auckland 1142, New Zealand
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Apr 2015, 3 months.

Results were first posted in Dec 2020, 5 years 7 months after primary completion.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 3 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2014
First posted
Nov 20, 2014
StartActual
Dec 22, 2014
Primary completionActual
Apr 17, 2015
CompletionActual
Apr 17, 2015
Results first posted
Dec 9, 2020
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02296853
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 20, 2014
Start date
Dec 22, 2014
Primary completion
Apr 17, 2015
Completion
Apr 17, 2015
Results posted
Dec 9, 2020
Last update
Dec 9, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion